MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Puma Biotechnology Inc

Open

SectorHealthcare

5.23 0.58

Overview

Share price change

24h

Current

Min

5.13

Max

5.28

Key metrics

By Trading Economics

Income

2.9M

5.9M

Sales

6.4M

52M

P/E

Sector Avg

5.081

37.257

Profit margin

11.166

Employees

172

EBITDA

6.8M

11M

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

-42.08% downside

Dividends

By Dow Jones

Next Earnings

6 lis 2025

Market Stats

By TradingEconomics

Market Cap

100M

258M

Previous open

4.65

Previous close

5.23

News Sentiment

By Acuity

50%

50%

183 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

7 paź 2025, 16:58 UTC

Earnings

BMW Trims 2025 View, Citing Weaker Performance in China

7 paź 2025, 23:43 UTC

Market Talk

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 paź 2025, 23:36 UTC

Market Talk

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 paź 2025, 23:19 UTC

Market Talk

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 paź 2025, 22:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 paź 2025, 22:50 UTC

Market Talk

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 paź 2025, 22:40 UTC

Market Talk

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 paź 2025, 21:56 UTC

Market Talk

Global Equities Roundup: Market Talk

7 paź 2025, 21:56 UTC

Market Talk

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 paź 2025, 20:44 UTC

Hot Stocks

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 paź 2025, 19:42 UTC

Market Talk

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 paź 2025, 19:23 UTC

Acquisitions, Mergers, Takeovers

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 paź 2025, 19:07 UTC

Market Talk

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 paź 2025, 19:02 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 paź 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

7 paź 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 paź 2025, 16:20 UTC

Market Talk

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 paź 2025, 16:15 UTC

Market Talk

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 paź 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 paź 2025, 15:37 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 paź 2025, 15:37 UTC

Market Talk

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 paź 2025, 15:33 UTC

Market Talk

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 paź 2025, 15:25 UTC

Market Talk

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 paź 2025, 15:15 UTC

Market Talk

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 paź 2025, 15:04 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

7 paź 2025, 15:04 UTC

Market Talk

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 paź 2025, 14:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7 paź 2025, 14:56 UTC

Market Talk

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 paź 2025, 14:52 UTC

Earnings

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-42.08% downside

12 Months Forecast

Average 3 USD  -42.08%

High 4 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

0

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

183 / 371 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat